Question 1

What’s the financial overview for Eli Lilly and Company?

Accepted Answer

Eli Lilly and Company’s market cap stands at $0.72 trillion right now. The company’s trailing twelve-month earnings per share EPS is $12.31, with a dividend yield of 0.73%. Their next earnings report is set for January 29, 2025, and the estimated EPS for that period is $1.61. You can also check out summaries of their income statement, balance sheet, and cash flow details for a fuller picture of their financials.

Question 2

How can I analyze historical data?

Accepted Answer

To analyze historical data with AI tools, apply the date range filter above the table to focus on a specific period. The table displays daily open, high, low, close prices, and volume, enabling you to spot trends and patterns. Use these insights to make informed decisions based on historical performance.

Question 3

What does Eli Lilly and Company Stock ROE tell us?

Accepted Answer

Eli Lilly and Company stock ROE shows positive market sentiment. A higher ROE means the company’s management is doing a better job at using equity financing to drive income and growth. It’s a handy metric for comparing how a company stacks up against its competitors or the broader market.

Question 4

What do Analysts say about Eli Lilly and Company?

Accepted Answer

8 number of Analysts recommended buying Eli Lilly and Company the stock and 1 analysts recommended selling the stock.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Revenue	$13.53B	$11.44B	$11.30B	$8.77B
Cost of Revenue	$2.40B	$2.17B	$2.17B	$1.67B
Gross Profit	$11.13B	$9.27B	$9.13B	$7.09B
Gross Profit Ratio	$0.82	$0.81	$0.81	$0.81
R&D Expenses	$3.21B	$2.73B	$2.71B	$2.52B
SG&A Expenses	$2.42B	$2.10B	$2.003B	$1.84B
Operating Expenses	$5.98B	$4.83B	$4.83B	$4.36B
Total Costs & Expenses	$8.38B	$7.005B	$7.00B	$6.14B
Interest Income	$0.00	$47.80M	$37.30M	$45.80M
Interest Expense	$180.40M	$192.70M	$183.60M	$179.60M
Depreciation & Amortization	$466.80M	$466.80M	$414.40M	$400.60M
EBITDA	$6.15B	$2.25B	$4.12B	$3.12B
EBITDA Ratio	$0.45	$0.20	$0.36	$0.36
Operating Income	$5.15B	$4.43B	$4.30B	$2.74B
Operating Income Ratio	$0.38	$0.39	$0.38	$0.31
Other Income/Expenses (Net)	-$110.10M	-$2.85B	-$786.90M	-$199.50M
Income Before Tax	$5.04B	$1.59B	$3.52B	$2.54B
Income Before Tax Ratio	$0.37	$0.14	$0.31	$0.29
Income Tax Expense	$628.90M	$618.10M	$550.20M	$293.20M
Net Income	$4.41B	$970.30M	$2.97B	$2.24B
Net Income Ratio	$0.33	$0.08	$0.26	$0.26
EPS	$4.88	$1.08	$3.29	$2.49
Diluted EPS	$4.88	$1.07	$3.28	$2.48
Weighted Avg Shares Outstanding	$903.65M	$901.00M	$900.90M	$900.80M
Weighted Avg Shares Outstanding (Diluted)	$903.16M	$905.00M	$904.20M	$903.80M

Eli Lilly and Company